Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52

Autor: Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadło-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Introduction SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.Methods Subjects were randomized to receive 45 mg of SB17 or UST

Externí odkaz: https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Autor: Gordon, K. B, Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., Cameron, G. S., Erickson, J., Konrad, R. J., Muram, T. M., Nickoloff, B. J., Osuntokun, O. O., Secrest, R. J., Zhao, F., Mallbris, L., Leonardi, C. L., Uncover, 1 Study Group: Holly Hake Harris, Matheson, Robert T., Michael, Bukhalo, John H., Tu, Crowley, Jeffrey J., Grande, Kimberly K., Adnan, Nasir, Boni Elizabeth Elewski, James Alan Solomon, Liebhild, Stratmann, Claudia, Buettner, Thomas Peter Dirschka, Margrit Ruth Simon, Jens, Ulrich, Christine, Grigat, Mathias, Augustin, Andrei, Khariouzov, Gerhard, Sattler, Hans Michael Ockenfels, Fredrick Richard Behringer, Hector, Wiltz, Francisco, Flores, Kuettel, Kevin D., Ira Hughes Thorla, Jeffrey Keith Moore, Waterman, Gary L., George Joji Murakawa, Scott Alfred Fretzin, Frankel, Ellen H., Sunil Sharan Dhawan, Lucyna, Leszniewska, Maria, Poznanska, Anna Sobieszek Kundro, Chodorowska, Grazyna M., Katarzyna Turek Urasinska, Romuald, Maleszka, Andrzej, Kaszuba, Lidia, Rajzer, Elizbieta Barbara Szymanska, Lidia, Rudnicka, Neil James Korman, Jamie Debra Weisman, Truett, Artis P., Jeffry, Jacqmein, Steven Robert Cohen, Heller, Gary L., Jenkin, Peter J., Abe, Marcadis, George Sorin Tiplica, Anca Aghinitei Zbranca Toporas, Simona Laura Ianosi, Ion, Florea, Claus, Zachariae, Lars, Iversen, Annalisa, Patrizi, Romanelli, Marco, Christopher, Griffiths, John Berth Jones, John, Foerster, Savin, Ronald C., Nelson, Christopher G., Lyn Carol Chamberlain Guenther, Albrecht, Lorne E., Hong, Chih ho H., Arnon, Katz, Mani, Raman, Adam, David N., Aamir, Butt, Stephen Peter Shumack, Kurt Aaron Josef Gebauer, Lynda Jane Spelman, Shireen Kaur Sidhu, Michael George Freeman, Peter Anthony Foley, Lajos, Kemeny, Eva, Remenyik, Zsuzsanna, Karolyi, Marc, Bourcier, Wayne Douglas Carey, Victoria, Taraska, Derek, Haaland, Aditya Kumar Gupta, Catherine, Maari, Darryl Paul Toth, Michael, Sebastian, Sandra, Philipp, Roland, Kaufmann, Diamant, Thaci, Thomas Andreas Werfel, Leila, Parise, Ingo, Haase, Petra Staubach Renz, Shinichi, Imafuku, Juichiro, Nakayama, Tadashi, Terui, Hideki, Nakajima, Shigetoshi, Sano, Uncover, 2 Study Group, Uncover, 3 Study Group

Publikováno v: New England Journal of Medicine. 375:345-356

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb30bf3a03c1849628a03f8c5fc3e43
https://doi.org/10.1056/nejmoa1512711

[The role of cytokines released by keratinocytes in psoriasis pathogenesis]

Autor: Lidia, Rajzer, Anna, Wojas-Pelc

Publikováno v: Przeglad lekarski. 66(3)

The paper presents epidemiology, pathogenesis, environmental triggers and types of psoriasis depending on the first psoriatic lesions. The immunological system by cytokines which source are keratinocytes, plays the important role in psoriatic course.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d6256eff011b4f12bc41e1b0f45e48a2
https://pubmed.ncbi.nlm.nih.gov/19689041

[Psoriasis and cardio-vascular disorders]

Autor: Anna, Wojas-Pelc, Lidia, Rajzer, Marek, Rajzer

Publikováno v: Przeglad lekarski. 59(10)

Psoriasis is one of the most frequent skin diseases. It occurs in adult people with a frequency 2-3%. Psoriasis is a systemic disease with immunologic and genetic determinants. Micro and macro vascular disorders are important for pathogenesis of psor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ed701a6d7ca7aa168d1a00413b5f4e87
https://pubmed.ncbi.nlm.nih.gov/12632926